Study participants were 134 individuals from the HYPOAGE cohort with insulin-treated T2D aged ≥ 75 years and using a continuous glycaemic-monitoring (CGM) device for 28 days. "Diabetes overtreatment" ...
Glass Lewis says it will end its ‘advice’ on shareholder votes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback